Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
16 reports, 5 independent
Updated Sun 00:00
Mostly repetition
- Reports
- 16
- Developments
- 3
- Repetition
- 88%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Medicare coverage expansion is driving patient volume for Eli Lilly products amid intense GLP-1 competition.1 source
- Novo Nordisk launched oral Wegovy in the U.S. while Medicare set co-pays for the bridge program, alongside soaring sales for Eli Lilly's drugs.Sub-event
Medicare coverage approved for obesity drugs from Novo Nordisk and Eli Lilly.1 source
Keep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
-
Medicare
US federal health insurance
Related events
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes.
- Medicare prescription changes affect Novo Nordisk's revenue outlook, coinciding with a Deutsche Bank stock downgrade.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.